Get the app
USHealthcare

Omnicell Inc (OMCL)

US · Healthcare · Health Information Services

$32.62+0.59%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$312.2M
Revenue YoY
+7.4%
Net profit
$24.3M
Profit YoY
+330.7%
EPS
$0.70
EPS estimate
$0.31
Net margin
7.8%

EPS came in at 0.70 against a street estimate of 0.31 — a beat of 125.8%.

Key statistics

Market cap
$1.49B
P/E
38.1
Forward P/E
29.5
P/B
1.14
Book value
$28.32
EPS (TTM)
$0.86
52-week high
$55.00
52-week low
$29.06
50-day MA
$38.65
200-day MA
$40.67
Beta
0.97

Analyst view

Analysts rate Omnicell Inc a buy (4 buy, 4 hold, 0 sell out of 8) with an average price target of $57.86.

From the latest earnings call · 2026-07-30

MIXED Strong Q2 beat on profitability ($0.94 EPS vs. $0.31 guide), but management widened full-year bookings range to $425–$560M, citing unpredictable enterprise deal timing. Titan XT early-stage traction and cloud platform OmniSphere remain on track. Q2 2026 Connected devices portfolio performing steadily across both North America and international markets. No region-specific breakdowns provided. Analysts probed the stark bookings range widening and competitive deal-timing extension. Management attributed both to multi-stakeholder enterprise sales cycles and simultaneous new-platform launches by both major competitors, not demand weakness. Emphasized pipeline strength and confidence in long-term opportunity. 2026-07-30…

Full summary in the app.

Shareholding

Insiders
2.15%
Institutions
108.08%

Largest institutional holders

FundStake
BlackRock Inc15.80%
Vanguard Portfolio Management, LLC7.05%
Wellington Management Company LLP5.92%
Dimensional Fund Advisors, Inc.5.38%
State Street Corp4.28%
Vanguard Capital Management, LLC4.24%
Millennium Management LLC3.80%
Delaware Management Holdings Inc2.59%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
OMNICELL, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (6M 2026): $622,088 thousand ($622.1 million), up from $560,230 thousand in
2026-08-05
Results announced · Q3 2026
OMNICELL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Report Date: July 30, 2026 for quarter ended June 30, 2026 (Q2 2026) • Company: Omnicell, Inc.
2026-07-30
Board / officer change · Q2 2026
OMNICELL, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Nnamdi Njoku appointed President of Omnicell, effective July 1, 2026, while retain
2026-07-01
Board / officer change · Q2 2026
OMNICELL, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • 1,600,000 additional shares authorized under equity incentiv
2026-05-26
Quarterly report · Q1 2026
OMNICELL, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Q1 2026 Total Revenues: $309.9 million (up from $269.7 million in Q1 2025, +14.9% grow
2026-05-06
Results announced · Q2 2026
OMNICELL, INC. - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $310 million, up $40 million or 15% year-over-year from $270 m
2026-04-28
Proxy statement · Q2 2026
OMNICELL, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Total 2025 compensation for CEO: Not explicitly stated in provided text; detai
2026-04-13
Annual report FY2025
OMNICELL, INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Public Company Status: Large accelerated filer on NASDAQ (ticker: OMCL),
2026-02-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Omnicell Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.